Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Roberts; Michael W. Deininger; Gerhard C. Hildebrandt; Brian K. Gackenbach; Maxwell M. Krem

doi:10.1080/10428194.2020.1808210

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Roberts
, Michael W. Deininger
, Gerhard C. Hildebrandt
, Brian K. Gackenbach
, Maxwell M. Krem

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	3507-3510
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	14
DOIs	https://doi.org/10.1080/10428194.2020.1808210
State	Published - 2020

Bibliographical note

Funding Information:
GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Funding

GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Funders	Funder number
Incyte
National Institutes of Health (NIH)
National Childhood Cancer Registry – National Cancer Institute	R01CA178397
Astellas Pharma Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1808210

Cite this

@article{920fa802d4ed47e68ca4f8002518b05e,

title = "Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia",

author = "Roberts, \{Kandice E.\} and Deininger, \{Michael W.\} and Hildebrandt, \{Gerhard C.\} and Gackenbach, \{Brian K.\} and Krem, \{Maxwell M.\}",

note = "Funding Information: GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.",

year = "2020",

doi = "10.1080/10428194.2020.1808210",

language = "English",

volume = "61",

pages = "3507--3510",

number = "14",

}

TY - JOUR

T1 - Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Roberts, Kandice E.

AU - Deininger, Michael W.

AU - Hildebrandt, Gerhard C.

AU - Gackenbach, Brian K.

AU - Krem, Maxwell M.

N1 - Funding Information: GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

PY - 2020

Y1 - 2020

UR - https://www.scopus.com/pages/publications/85089783902

UR - https://www.scopus.com/pages/publications/85089783902#tab=citedBy

U2 - 10.1080/10428194.2020.1808210

DO - 10.1080/10428194.2020.1808210

M3 - Letter

C2 - 32835547

AN - SCOPUS:85089783902

SN - 1042-8194

VL - 61

SP - 3507

EP - 3510

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 14

ER -

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Bibliographical note

Funding

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this